Frank Yocca, Chief Scientific Officer at BioXcel Therapeutics, Inc. (BTAI), bought 900 shares at $5.20 ($5K) on 2018-12-04, disclosed to the SEC on 2018-12-06.
Open-market purchase of $5k BTAI by Chief Scientific Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.23 | 450 | $2K | 50.1% |
| 2 | $5.20 | 450 | $2K | 49.9% |
| Total | $5.21 avg | 900 | $5K | 100% |
| Filing → |
| BTAI | SELL | 2024-10-03 | $4K | — | Filing → |
| BTAI | SELL | 2024-09-17 | $245 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $476 | — | Filing → |